,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-10-24 07:08:00,"BostonScientific ( BSX ) reported adjusted earnings per share (after considering certain one-time adjustments other than amortization expense) of 10 cents in the third quarter of 2013, in line with the year-ago adjusted EPS figure.",0.8418554663658142,0.031667985022068024,0.12647661566734314,positive,0.8101874589920044
1,2013-10-24 07:08:00,"However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 17 cents, beating the year-ago adjusted EPS by a penny.",0.8747511506080627,0.09469573944807053,0.03055315650999546,positive,0.7800554037094116
2,2013-10-24 07:08:00,This also exceeded the company's adjusted EPS guidance range of 14-16 cents.,0.9248389005661011,0.024004217237234116,0.05115682631731033,positive,0.9008346796035767
3,2013-10-24 07:08:00,The Zacks Consensus Estimate for the reported quarter was 17 cents.,0.02239098772406578,0.0895303413271904,0.8880786299705505,neutral,-0.06713935732841492
4,2013-10-24 07:08:00,"However, without these adjustments, the company reported net loss of $5 million, or break-even EPS in the quarter, comparing favorably with year-ago net loss of $663 million or a loss of 48 cents a share.",0.0344974659383297,0.9476314783096313,0.017871025949716568,negative,-0.9131340384483337
5,2013-10-24 07:08:00,"Revenues remained flat year over year (up 4% at constant exchange rate or CER, excluding divested business) at $1.735 billion.",0.05368296802043915,0.9212141036987305,0.025102859362959862,negative,-0.8675311207771301
6,2013-10-24 07:08:00,"Although the figure exceeded the Zacks Consensus Estimate of $1.729 billion, it remained within the company-provided guidance range of $1.700−$1.860 billion.",0.7493104338645935,0.06516354531049728,0.185526043176651,positive,0.6841468811035156
7,2013-10-24 07:08:00,"The company also presented an encouraging performance in the BRIC (Brazil, Russia, India and China) nations with 28% (29% at CER) year-over-year sales growth during the quarter.",0.9557355046272278,0.01823011413216591,0.026034420356154442,positive,0.9375053644180298
8,2013-10-24 07:08:00,"Boston Scientific currently has three global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.",0.020252270624041557,0.006100116763263941,0.9736475944519043,neutral,0.014152154326438904
9,2013-10-24 07:08:00,"The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions.",0.028852129355072975,0.00474511319771409,0.9664027690887451,neutral,0.024107016623020172
10,2013-10-24 07:08:00,"Sales in these sub-segments were $472 million (down 2% year over year at CER) and $195 million (up 7% at CER), respectively, during the quarter.",0.01948138140141964,0.9640360474586487,0.016482530161738396,negative,-0.9445546865463257
11,2013-10-24 07:08:00,"Global sales of coronary stent system (within Interventional Cardiology) were $277 million, down 8.9%.",0.018246039748191833,0.9698179364204407,0.011936093680560589,negative,-0.9515718817710876
12,2013-10-24 07:08:00,"The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 7.4% to $262 million, and bare-metal stents that plunged 28.6% to $15 million.",0.019473712891340256,0.9687367081642151,0.011789551936089993,negative,-0.9492629766464233
13,2013-10-24 07:08:00,"The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.",0.06994349509477615,0.005626555532217026,0.9244298934936523,neutral,0.06431694328784943
14,2013-10-24 07:08:00,This segment also continued to disappoint with flat third-quarter revenues of $498 million on a year-over-year basis (up 1% at CER).,0.03136296197772026,0.9570136070251465,0.011623479425907135,negative,-0.9256506562232971
15,2013-10-24 07:08:00,Worldwide CRM revenues remained flat at $464 million.,0.016205033287405968,0.9466421604156494,0.03715275228023529,negative,-0.9304371476173401
16,2013-10-24 07:08:00,"Sales from pacemakers were down 0.7% to $134 million, while defibrillators edged up 0.9% to $330 million.",0.017542989924550056,0.9703763723373413,0.012080571614205837,negative,-0.952833354473114
17,2013-10-24 07:08:00,Electrophysiology sales deteriorated 3% year over year (down 1% at CER) to $34 million.,0.20030559599399567,0.782359778881073,0.01733463816344738,negative,-0.5820541977882385
18,2013-10-24 07:08:00,"Over the recent past, the company has been targeting new product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments.",0.9060390591621399,0.012852884829044342,0.08110802620649338,positive,0.8931861519813538
19,2013-10-24 07:08:00,"However, the dismal performance of these segments during the reported quarter proved beyond doubt that these measures have not been enough to counter the ongoing challenges.",0.12093035876750946,0.845648467540741,0.03342117369174957,negative,-0.7247180938720703
20,2013-10-24 07:08:00,"Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $322 million (up 8% at CER), $131 million (up 8%) and $115 million (up 32%), respectively.",0.8743838667869568,0.017678899690508842,0.10793716460466385,positive,0.8567049503326416
21,2013-10-24 07:08:00,Gross margin grew 277 basis points (bps) year over year to 70.6%.,0.9580891728401184,0.01837102882564068,0.023539826273918152,positive,0.9397181272506714
22,2013-10-24 07:08:00,Adjusted operating margin however contracted 98 bps to 18.6% in the quarter.,0.893322765827179,0.0954732745885849,0.011203969828784466,positive,0.7978494763374329
23,2013-10-24 07:08:00,"During the reported quarter, selling, general and administrative expenses grew 11.7% to $658 million, research and development expenses dropped 1.4% to $217 million and royalty expense declined 3.4% to $28 million.",0.02437407337129116,0.9627036452293396,0.012922178022563457,negative,-0.9383295774459839
24,2013-10-24 07:08:00,"Boston Scientific exited the quarter with cash and cash equivalents of $571 million, up from $207 million at the end of fiscal 2012 and had long-term debt of $4.25 billion.",0.9495518803596497,0.018299298360943794,0.03214883431792259,positive,0.9312525987625122
25,2013-10-24 07:08:00,The company generated operating cash flow of $250 million and repurchased 6.8 million shares during the quarter under the existing share repurchase program.,0.31843632459640503,0.00993270892649889,0.6716309189796448,neutral,0.3085036277770996
26,2013-10-24 07:08:00,Boston Scientific provided its fourth-quarter guidance and updated its fiscal 2013 outlook.,0.0964163988828659,0.007277606520801783,0.896306037902832,neutral,0.08913879096508026
27,2013-10-24 07:08:00,"In the upcoming quarter, the company expects to report adjusted EPS of 18-20 cents (considering amortized expense adjustments) on revenues of $1.780 to $1.830 billion.",0.23413711786270142,0.01981516182422638,0.7460476756095886,neutral,0.21432195603847504
28,2013-10-24 07:08:00,"The current Zacks Consensus Estimate for EPS of 20 cents coincides with the higher end of the company's outlook, although the same for revenues of $1.819 billion falls within the company's guidance.",0.11073184013366699,0.04219246655702591,0.8470757603645325,neutral,0.06853937357664108
29,2013-10-24 07:08:00,"For full year 2013, the company tightened its revenue guidance to the band of $7.085−$7.135 billion (the earlier provided range being $7.050­­­−$7.170 billion).",0.412893682718277,0.14014019072055817,0.44696614146232605,neutral,0.2727534770965576
30,2013-10-24 07:08:00,Adjusted EPS was narrowed to the range of 69−71 cents from 67−71 cents guided previously.,0.6923050880432129,0.18373914062976837,0.12395580112934113,positive,0.5085659623146057
31,2013-10-24 07:08:00,"The Zacks Consensus Estimate for revenues stands at $7.120 billion, while that for EPS is 70 cents.",0.015497050248086452,0.04345695301890373,0.9410459995269775,neutral,-0.027959901839494705
32,2013-10-24 07:08:00,"During the earnings call, Boston Scientific also announced a restructuring program for 2014.",0.4567011594772339,0.050900377333164215,0.4923985004425049,neutral,0.40580078959465027
33,2013-10-24 07:08:00,"Major actions under this plan includes continued implementation of the company's ongoing Plant Network Optimization strategy, continued focus on driving operational efficiencies and current business and commercial model changes.",0.5427124500274658,0.010020839050412178,0.44726666808128357,positive,0.5326915979385376
34,2013-10-24 07:08:00,The company expects this plan to reduce gross annual pre-tax operating expenses by $150−$200 million by the end of 2015.,0.2620345950126648,0.6131859421730042,0.12477945536375046,negative,-0.35115134716033936
35,2013-10-24 07:08:00,"It also plans to make savings through this restructuring program, to reinvest a part of it in strategic growth initiatives.",0.8774102330207825,0.012061319313943386,0.11052844673395157,positive,0.8653489351272583
36,2013-10-24 07:08:00,"According to BSX, this will lead to around 1,100−1,500 job cuts worldwide through attrition and targeted headcount reductions.",0.026940617710351944,0.9587463736534119,0.01431293971836567,negative,-0.9318057298660278
37,2013-10-24 07:08:00,The company expects this program to be brought into effect from the fourth quarter of 2013 through 2015.,0.12294533848762512,0.0054273479618132114,0.8716272711753845,neutral,0.11751799285411835
38,2013-10-24 07:08:00,"In a separate press release, Boston scientific also announced that its existing executive vice president and chief financial officer Jeffrey Capello will shed off his role effective Dec 31, 2013.",0.021424440667033195,0.7918879985809326,0.18668754398822784,negative,-0.7704635858535767
39,2013-10-24 07:08:00,"Daniel Brennan, currently the company's senior vice president and corporate controller, will be taking up his position thereon.",0.020378222689032555,0.015009836293756962,0.9646119475364685,neutral,0.005368386395275593
40,2013-10-24 07:08:00,Boston Scientific managed to beat estimates in the third quarter of 2013.,0.9362217783927917,0.03834894672036171,0.025429310277104378,positive,0.897872805595398
41,2013-10-24 07:08:00,"However, challenging economic conditions, competitive environment, pressure on core segments and currency fluctuations remain major headwinds.",0.025292590260505676,0.9027597904205322,0.07194768637418747,negative,-0.8774672150611877
42,2013-10-24 07:08:00,"Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments, implantable cardioverter defibrillator and DES continue to face challenges.",0.4622749090194702,0.2061317265033722,0.3315933644771576,positive,0.256143182516098
43,2013-10-24 07:08:00,The US defibrillator market remains an overhang for Boston Scientific and its peers.,0.11107325553894043,0.31699010729789734,0.5719366669654846,neutral,-0.2059168517589569
44,2013-10-24 07:08:00,"The DES business in the U.S. has been witnessing challenges due to pricing pressure, lower procedural volume, lower penetration rates and share losses from the launch of Medtronic 's ( MDT ) Resolute Integrity stent.",0.023452607914805412,0.955966591835022,0.02058073692023754,negative,-0.9325140118598938
45,2013-10-24 07:08:00,"However, to revive its top line, Boston Scientific is focusing on strategic initiatives to drive growth and profitability.",0.9141353964805603,0.013334576971828938,0.072530098259449,positive,0.9008008241653442
46,2013-10-24 07:08:00,"These include the recently announced restructuring initiatives, strengthening of its portfolio, targeting suitable acquisitions in areas of unmet medical needs, and focus on emerging markets.",0.8153162598609924,0.010731857270002365,0.17395184934139252,positive,0.8045843839645386
47,2013-10-24 07:08:00,"However, near-term visibility of these initiatives remains a matter of question.",0.034571994096040726,0.014743928797543049,0.9506840705871582,neutral,0.01982806622982025
48,2013-10-24 07:08:00,"Currently, Boston Scientific retains a Zacks Rank #2 (Buy).",0.24157434701919556,0.01166945043951273,0.7467561960220337,neutral,0.2299048900604248
49,2013-10-24 07:08:00,"MedTech companies such as Mindray Medical International Ltd ( MR ) and Bio-Rad Laboratories, Inc. ( BIO ), which carry a Zacks Rank #1 (Strong Buy), are also worth considering.",0.6735430359840393,0.013171076774597168,0.31328582763671875,positive,0.6603719592094421
50,2013-10-24 07:08:00,To read this article on Zacks.com click here.,0.01796119473874569,0.0192450862377882,0.9627937078475952,neutral,-0.001283891499042511
51,2013-10-24 07:08:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
